Authors:

Paavani Reddy, MD

Paavani is a 2nd year resident in the MGH/McLean Psychiatry Residency Program. She grew up in Cleveland, Ohio, and went to college and medical school in the Chicago area at Northwestern University. She is interested in early family mental health and consult-liaison psychiatry. She enjoys scouting dessert spots, as well as reading on the Esplanade.

Nadia Quijije, MD

Dr. Quijije obtained her medical doctorate from SUNY Downstate Health Sciences University, completed her psychiatric residency at the University of South Florida, a Consultation Liaison Fellowship at Massachusetts General Hospital, a Fellowship in Psychotherapy at the Boston Psychoanalytic Society and Institute (BPSI), and is currently in psychoanalytic training at BPSI. Dr. Quijije is a psychiatrist on the Acute Psychiatric Service, Consultation Liaison Psychiatry Service, and Ketamine Clinic at MGH and also has a private practice.

Caitlin Adams, MD

Caitlin Adams is an attending psychiatrist who completed a fellowship in CL psychiatry at MGH. She is currently working as an attending psychiatrist in the departments of Psychiatry and Neurology. She has built an embedded psychiatry clinic within the division of cognitive and behavioral neurology. Her clinical interests include diagnoses at the interface of medicine and psychiatry as well as at the interface of neurology and psychiatry. She currently serves as the Functional Neurological Disorder SIG Chair for the American Neuropsychiatric Association, is a founding member of the Functional Neurological Disorder Society, and was co-president of the Boston Society of Neurology, Neurosurgery, and Psychiatry from 2023-2024.

Pedram Heidari, MD

Pedram Heidari, MD, is a physician-scientist and nuclear radiologist at Massachusetts General Hospital (MGH) and Assistant Professor of Radiology at Harvard Medical School. He serves as the Service Chief of Nuclear Medicine and Molecular Imaging at MGH and Director of the MGH PET Core. Dr. Heidari’s work lies at the intersection of precision molecular imaging, radiopharmaceutical therapy (RPT), and translational oncology, with a focus on theranostic approaches to cancer care.

Dr. Heidari joined the MGH faculty in 2018. He has since built one of the largest radiopharmaceutical therapy programs in North America, integrating advanced dosimetry and AI-based imaging analysis into clinical workflows. His research focuses on the development and translation of novel radiotracers for imaging and therapy, with recent projects targeting tumor microenvironment markers, apoptosis, and immune modulation. He leads the "Bio-dosimetry" pillar of a major institutional initiative, evaluating biological surrogates of radiation response using PET imaging biomarkers.

Dr. Heidari has trained numerous clinical and research fellows and actively participates in national and international imaging consortia. He holds several NIH and foundation grants, has published extensively in high-impact journals, and serves on national grant review panels and editorial boards. Dr. Heidari’s leadership has positioned MGH as a hub for innovation in molecular imaging and radiotheranostics, fostering collaborations across academia and industry to drive forward the next generation of cancer diagnostics and therapies.

Michelle Rengarajan, MD

Dr. Rengarajan received a B.A. from the University of Chicago and an M.D. and Ph.D. from Stanford University. She completed her residency in Internal Medicine at Brigham and Women’s Hospital and her endocrinology fellowship at Massachusetts General Hospital. Dr. Rengarajan specializes in treating endocrine disorders, with a particular focus on thyroid disorders, endocrine autoimmunity, and immunotherapy toxicities. She is an attending in MGH Thyroid Associates and on the Severe Immunotherapy Complications team. Dr. Rengarajan conducts translational research on autoimmune endocrine diseases, such as Hashimoto’s thyroiditis, Graves' disease, and type 1 diabetes. She is additionally involved in clinical and translational research related to endocrinologic complications of cancer immunotherapy.

Case Organizer:

Daniel Restrepo, MD, FHM

Dr. Restrepo is a board-certified general internist and hospitalist in the Department of Medicine, a member of the Core Educator Faculty, and the Associate Program Director for Point-of-Care Ultrasound for the internal medicine residency program at the Massachusetts General Hospital, as well as an Assistant Professor of Medicine at Harvard Medical School. He additionally serves as the Associate Editor for the Case Records of the Massachusetts General Hospital in the New England Journal of Medicine (also known as the CPCs) and is the Co-Director of the Clinical Reasoning Curriculum for the MGH medical residents.

He graduated with a degree in biology from the University of Florida and attended medical school at the University of South Florida College of Medicine. He completed his internal medicine residency and later chief residency at Massachusetts General Hospital. His main interests lie in diagnostic reasoning, clinical and bedside teaching, as well as physical diagnosis and point-of-care ultrasound.